Inotiv, Inc. NOTV
We take great care to ensure that the data presented and summarized in this overview for Inotiv, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NOTV
View all-
Vanguard Group Inc Valley Forge, PA1.05MShares$4.29 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN268KShares$1.09 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA251KShares$1.02 Million0.0% of portfolio
-
Kpp Advisory Services LLC Louisville, KY238KShares$969,8890.1% of portfolio
-
Black Rock Inc. New York, NY213KShares$868,1660.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY187KShares$763,2820.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny171KShares$697,9410.0% of portfolio
-
Parian Global Management LP Pound Ridge, NY137KShares$558,5807.5% of portfolio
-
Oak Family Advisors, LLC108KShares$441,8190.06% of portfolio
-
Invenire Partners, LP Ridgefield, CT95KShares$387,600100.0% of portfolio
Latest Institutional Activity in NOTV
Top Purchases
Top Sells
About NOTV
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Insider Transactions at NOTV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 10
2024
|
John Gregory Beattie Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+15.64%
|
$120,000
$4.75 P/Share
|
Dec 10
2024
|
Nigel Brown Director |
BUY
Open market or private purchase
|
Direct |
7,500
+10.27%
|
$30,000
$4.26 P/Share
|
Dec 06
2024
|
David Landman Director |
BUY
Open market or private purchase
|
Direct |
100,000
+39.48%
|
$400,000
$4.14 P/Share
|
Dec 06
2024
|
Michael J Harrington Director |
BUY
Open market or private purchase
|
Direct |
10,000
+21.05%
|
$30,000
$3.98 P/Share
|
Aug 10
2024
|
Robert Leasure Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+22.17%
|
-
|
Aug 10
2024
|
David Landman Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+34.03%
|
-
|
Aug 10
2024
|
John Gregory Beattie Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+13.18%
|
-
|
Aug 10
2024
|
R Matthew Neff Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+19.2%
|
-
|
Aug 10
2024
|
Nigel Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+32.15%
|
-
|
Aug 10
2024
|
Adrian Hardy Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+37.44%
|
-
|
Aug 10
2024
|
Michael J Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+50.0%
|
-
|
Aug 10
2024
|
Andrea Castetter SVP, Gen. Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
Aug 10
2024
|
Beth Taylor Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+14.84%
|
-
|
Aug 10
2024
|
Jeffrey Arthur Krupp Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+39.17%
|
-
|
Aug 10
2024
|
Jeffrey Brennan Freeman VP-Finance & Corp. Controller |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+40.97%
|
-
|
Aug 10
2024
|
John E Sagartz Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+2.73%
|
-
|
Aug 10
2024
|
Mary Theresa Coelho Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+40.49%
|
-
|
Dec 14
2023
|
John Gregory Beattie Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
47,966
+30.03%
|
$143,898
$3.12 P/Share
|
Dec 14
2023
|
Michael Garrett Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+23.29%
|
$10,000
$2.83 P/Share
|
Oct 17
2023
|
Mary Theresa Coelho Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,911
+50.0%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 578K shares |
---|---|
Open market or private purchase | 148K shares |